^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
allogeneic Myeloma GM-CSF Vaccine
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sidney Kimmel Comprehensive Cancer Center
Drug class:
Immunostimulant, GM-CSF agonist
Related drugs:
6ms
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov)
P2, N=54, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2024 --> Dec 2024
Trial completion date
|
lenalidomide • allogeneic Myeloma GM-CSF Vaccine
Share via
